ADAM17 can mediate the release of sTNFR1 and sTNFR2, which inhibit the secretion of metastasis-promoting chemokines (CXCL8, CCL5, CXCL) and induce anti-metastasis effects in triple-negative breast cancer cells (203). Here, ADAM17 is linked to triple-negative breast carcinoma.